CCNYL1

Across TCGA pan-cancer cohorts, CCNYL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCNYL1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCNYL1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCNYL1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where CCNYL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.466	0.940	.024	6	view →
LSCC	DFS	Median	All	0.612	0.808	.015	5	view →
LUAD	DFS	Median	III,IV	0.342	0.646	.043	3	view →
CCRCC	OS	Tertile	IV	0.789	0.109	.036	3	view →
HNSC	OS	Quartile	III,IV	0.982	0.739	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCNYL1–PDAC (DFS)

Open the PDAC breakdown →